


U.S. Application No. 09/738,742

Attorney Docket No. C058


AMENDMENTS TO THE CLAIMS

1. (Previously presented) A compound having the formula (I):



and salts thereof;

wherein R is:



wherein X and X' are independently selected from C=O, C=S, C=NH, C=NR^X, S=O or SO₂;

wherein n is 1;

wherein R^x is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;

wherein B is X^mR^Y , H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and

U.S. Application No. 09/738,742


Attorney Docket No. C058

heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;

wherein A' is H, NH₂, NHR^{A'}, NR^{A'}R^{B'}, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl or heterocyclyl;

wherein R^{A'} and R^{B'} are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy;


wherein when m is 0, then A' is additionally selected from the group consisting of:



wherein each of R⁵⁰-R⁵³ is independently selected from C₁-C₁₅ alkyl;

alternatively, wherein B' and A' together form a 5-7 membered heterocyclic or heteroaryl ring;

wherein R² is




wherein K and K' together form a C₃-C₇ cycloalkyl or heterocyclyl ring or a C₅-C₁₀ aryl or heteroaryl ring;

wherein J is selected from the group consisting of hydrido, amino, NHR^J, NR^JR^K, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl, heterocyclyl,

U.S. Application No. 09/738,742

Attorney Docket No. C058

alkylamino, hydroxyl, thio, alkylthio, alkenylthio, sulfinyl, sulfonyl, azido, cyano, halo,




wherein each of R^{24} , R^{25} , and R^{26} is independently selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; or R^{24} and R^{25} together form a 5-8 membered heterocyclyl ring;

wherein R^J and R^K are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; or

alternatively, wherein J, together with R^{17} , forms a 5-8 membered heterocyclyl or cycloalkyl ring; or


alternatively, wherein J, together with both R^{17} and R^{18} , forms a 5-8 membered aryl, cycloalkyl, heterocyclyl or heteroaryl ring; and

wherein each of R^{17} and R^{18} is independently selected from the group consisting of hydrido, halo, hydroxyl, alkoxy, amino, thio, sulfinyl, sulfonyl and



; or

wherein R^{17} and R^{18} taken together can form a group consisting of ketal, thioketal,




wherein each of R^{22} and R^{23} is independently selected from the group

U.S. Application No. 09/738,742

Attorney Docket No. C058


consisting of hydrido and alkyl.

2. (Previously presented) A compound having the formula (I):



and salts thereof;

wherein R is:



wherein X and X' are independently selected from C=O, C=S, C=NH, C=NR^x, S=O or SO₂;

wherein n is 1;

wherein R^x is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;

wherein B is X''R^y, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl

U.S. Application No. 09/738,742


Attorney Docket No. C058

wherein $R^{Y'}$ is selected from hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;

wherein A' is H, NH_2 , $NHR^{A'}$, $NR^{A'}R^{B'}$, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl or heterocyclyl;

wherein $R^{A'}$ and $R^{B'}$ are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy;


wherein when m is 0, then A' is additionally selected from the group consisting of:



wherein each of R^{50} - R^{53} is independently selected from C_1 - C_{15} alkyl;

alternatively, wherein B' and A' together form a 5-7 membered heterocyclic or heteroaryl ring;

wherein R^2 is




wherein K and K' together form a C_3 - C_7 cycloalkyl or heterocyclyl ring or a C_5 - C_{10} aryl or heteroaryl ring;

wherein J is selected from the group consisting of hydrido, amino, NHR^J ,

U.S. Application No. 09/738,742

Attorney Docket No. C058

NR^JR^K, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylamino, hydroxyl, thio, alkylthio, alkenylthio, sulfinyl, sulfonyl, azido, cyano, halo,




wherein each of R²⁴, R²⁵, and R²⁶ is independently selected from the group consisting of alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; or R²⁴ and R²⁵ together form a 5-8 membered heterocyclyl ring;

wherein R^J and R^K are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; or

alternatively, wherein J, together with R¹⁷, forms a 5-8 membered heterocyclyl or cycloalkyl ring; or


alternatively, wherein J, together with both R¹⁷ and R¹⁸, forms a 5-8 membered aryl, cycloalkyl, heterocyclyl or heteroaryl ring; and

wherein each of R¹⁷ and R¹⁸ is independently selected from the group consisting of hydrido, halo, hydroxyl, alkoxy, amino, thio, sulfinyl, sulfonyl and



; or

wherein R¹⁷ and R¹⁸ taken together can form a group consisting of ketal, thioketal,




U.S. Application No. 09/738,742

Attorney Docket No. C058

wherein each of R^{22} and R^{23} is independently selected from the group consisting of hydrido and alkyl.

Claims 3-4 (Canceled)

5. (Previously presented) The compound according to claim 1, wherein R is selected from the group consisting of:




wherein each of R^3 , R^4 , R^5 , and R^6 is independently selected from the group consisting of hydrido, alkyl, aryl, heterocyclyl and heteroaryl, and wherein R^{200} is selected from the group consisting of hydrido, heterocyclyl, and heteroaryl.

6. (Previously presented) The compound according to claim 5, wherein R is selected from


U.S. Application No. 09/738,742

Attorney Docket No. C058




and wherein $R^{4'}$ is selected from the group consisting of heteroaryl, and heterocyclyl.

7. (Previously presented) The compound according to claim 6, wherein R is



8. (Currently amended) The compound according to either of claims 1 or 2, wherein R^1 is selected from the group consisting of:



U.S. Application No. 09/738,742

Attorney Docket No. C058


wherein R^8 is selected from a natural amino acid side chain or an amino acid side chain that is not naturally occurring;

wherein each of R^9 , R^{10} and R^{11} is selected from the group consisting of hydrido, alkyl, aryl, heterocyclyl and heteroaryl;

wherein R^{12} is selected from the group ~~consisting~~ consisting of heterocyclyl, heteroaryl, aryl, and alkyl and

wherein R^{13} is selected from (C₁-C₃-alkyl) and aryl.

9. (Currently amended) The compound according to claim 8, wherein R^1 is selected from the group consisting of:



wherein R^8 is selected from tryptophan side chain and lysine side chain;

wherein each of R^{10} and R^{11} is independently selected from hydrido and alkyl;


wherein R^{12} is selected from imidazolyl, N-methylimidazolyl, indolyl, quinolinyl, benzyloxybenzyl, and benzylpiperidenylbenzyl; and

U.S. Application No. 09/738,742


Attorney Docket No. C058

wherein X^4 is selected from fluoro, and or trifluoromethyl.

10. (Previously presented) The compound according to either of claims 1 or 2, wherein J is selected from the group consisting of hydrido, amino, azido and




wherein R^{17} and R^{18} taken together form a group selected from ketal,




or wherein R^{17} is hydroxyl when R^{18} is hydrido;

or wherein J, together with R^{17} , forms a heterocyclyl ring.

11. (Original) The compound according to claim 10, wherein R^2 is selected from the group consisting of




and




U.S. Application No. 09/738,742

Attorney Docket No. C058


wherein R^{17} and R^{18} taken together form a group selected from



, wherein R^{22} is selected from the group consisting of H and alkyl; and wherein R^{19} is selected from the group consisting of hydrido, amino,



12. (Original) The compound according to claim 11, wherein R^2 is



Claims 13-14 (Canceled)

15. (Previously presented) A pharmaceutical composition comprising the compound according to either of claims 1 or 2 and a pharmaceutically acceptable carrier.

16. (Currently amended) A method of treating ~~or preventing~~ a bacterial infection in a subject, comprising the step of administering a therapeutically-effective amount of the pharmaceutical composition according to claim 15 to a subject in need thereof for a time and under conditions effective to control or eliminate said bacterial infection.

U.S. Application No. 09/738,742

Attorney Docket No. C058

17. (Currently amended) The method according to claim 16, wherein said subject is selected from the group consisting of a human, an animal, a cell culture ~~or~~ and a plant.

18. (Original) The method according to claim 16, wherein said bacterial infection is caused by a gram-positive bacteria.

19. (Original) The method according to claim 18, wherein said bacteria is an antibiotic-resistant bacteria.

20. (Original) The method according to claim 19, wherein said antibiotic-resistant bacteria are resistant to an antibiotic selected from the group consisting of vancomycin, methicillin, glycopeptide antibiotics, penicillin and daptomycin.

21. (Original) The method according to claim 16, further comprising the step of co-administering more than one compound of Formula (I) to a subject in need thereof.

22. (Original) The method according to claim 16, further comprising the step of co-administering an antimicrobial agent other than a compound of Formula (I) to a subject in need thereof.

23. (Previously presented) The method according to claim 22, wherein said antimicrobial agent is selected from the group consisting of penicillins, carbapenems, cephalosporins, aminoglycosides, bacitracin, gramicidin, mupirocin, chloramphenicol, thiamphenicol, fusidate sodium, lincomycin, clindamycin, macrolides, novobiocin,

U.S. Application No. 09/738,742

Attorney Docket No. C058

polymyxins, rifamycins, spectinomycin, tetracyclines, vancomycin, teicoplanin, streptogramins, anti-folate agents, trimethoprim, pyrimethamine, synthetic antibacterials, nitroimidazoles, quinolones, fluoroquinolones, isoniazid, ethambutol, pyrazinamide, para-aminosalicylic acid (PAS), cycloserine, capreomycin, ethionamide, prothionamide, thiacetazone, viomycin, everninomicin, glycopeptide, glycyclcyclinc, ketolides, oxazolidinones, imipenen, amikacin, netilmicin, fosfomycin, gentamicin, ceftriaxone, Ziracin (56-deacetyl-57-demethyl-45-O-de(2-methyl-1-oxopropyl)-12-O-(2,3,6-trideoxy-3-C-methyl-4-O-methyl-3-nitro-alpha-L-arabino-hexopyranosyl)flambamycin), LY333328 (oritavancin), Linczolid (N-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide), Synercid (dalbapristin-quinupristin), Aztreonam (2-[[[(Z)-[1-(2-amino-4-thiazolyl)-2-[[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidiny] amino]-2-oxoethylidene]amino]oxy]-2-methyl-propanoic acid), Metronidazole (2-methyl-5-nitro-1H-imidazole-1-ethanol), Epiroprim (5-[[[3,5-diethoxy-4-(1H-pyrrol-1-yl)phenyl]methyl]-2,4-pyrimidinediamine), OCA-983 (1-[[[(2S)-2-amino-3-methyl-1-oxobutyl]amino]-2,5-anhydro-3-S-[(4R,5S,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]-1,4-dideoxy-3-thio-D-threo-pentitol), GV-143253 (trinem), Sanfetrinem ((1S, 5S, 8aS, 8bR)-1, 2, 5, 6, 7, 8, 8a, 8b-octahydro-1-[(1R)-1-hydroxyethyl]-5-methoxy-2-oxo-azeto[2,1-a]isoindole-4-carboxylic acid), CS-834 ((4R, 5S, 6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[[(3R)-5-oxo-3-pyrrolidinyl]thio]-1-azabicyclo [3.2.0]hept-2-ene-2-carboxylic acid (2,2-dimethyl-1-oxopropoxy)methyl ester), Biapenem (6-[[[(4R,5S,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6, 7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium inner salt), KA 159 (stipiamide), Dynemicin A ((1S,4R,4aR,14S,14aS,18Z)-1,4,7,12,13, 14-hexahydro-6,8,11-trihydroxy-3-methoxy-1-methyl-7,12-dioxo-4a,14a-epoxy-4,14-[3]hexenc[1,5]diynonaphtho[2,3-c]phenanthridine-

U.S. Application No. 09/738,742

Attorney Docket No. C058

2-carboxylic acid), DX8739 ((4R,5S,6S)-3-[[[(3S,5S)-5-[[4-[(2S)-5-amino-2-hydroxy-1-oxopentyl]-1-piperazinyl]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), DU 6681 ((4R,5S,6S)-3-[[[(6S)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), Cefluprenam ((2E)-N-(2-amino-2-oxoethyl)-3-[(6R,7R)-7-[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)](fluoromethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)-N-ethyl-N-methyl-2-propen-1-aminium inner salt), ER 35786 ((4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[[[(3S,5S)-5-[(R)-hydroxy(3R)-3-pyrrolidinylmethyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrochloride), Cefoselis ((6R,7R)-7-[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[2,3-dihydro-2-(2-hydroxyethyl)-3-imino-1H-pyrazol-1-yl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid), Sanfetrinem celexetil ((1S,5S,8aS,8bR)-1,2,5,6,7,8,8a,8b-octahydro-1-[(1R)-1-hydroxyethyl]-5-methoxy-2-oxo-2-azetido[2,1-a]isoindole-4-carboxylic acid 1-[(cyclohexyloxy)carbonyl]oxy]ethyl ester), Cefpirome (1-[[[(6R,7R)-7-[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-6,7-dihydro-5H-cyclopenta[b]pyridinium inner salt), HMR-3647 (3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]-erythromycin), RU-59863 (C-7 catechol substituted cephalosporin), KP 736 ((6R,7R)-7-[[[(2Z)-(2-amino-4-thiazolyl)][(1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl)methoxy]imino]acetyl]amino]-8-oxo-3-[(1,2,3-thiadiazol-5-ylthio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid disodium salt), Rifalazil (1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5'-[4-(2-methylpropyl)-1-piperazinyl]-1-oxo-

U.S. Application No. 09/738,742

Attorney Docket No. C058

rifamycin VIII), MEN 10700 ((5R,6S)-3-[[[(2-amino-2-oxoethyl)methylamino]methyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), Lenapenem ((4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[[[(3S,5S)-5-[(1R)-1-hydroxy-3-(methylamino)propyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), BO 2502A ((4R,5S,6S)-3-[(2S,3'S,4S)-[2,3'-bipyrrolidin]-4-ylthio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), NE-1530 (3'-sialyllacto-N-neotetraose), PR 39 (L-arginyl-L-arginyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-prolyl-L-tyrosyl-L-leucyl-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-prolyl-L-prolyl-L-phenylalanyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-leucyl-L-prolyl-L-prolyl-L-arginyl-L-isoleucyl-L-prolyl-L-prolyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-phenylalanyl-L-prolinamide [SEQ ID NO: 1]), K130 (5-[[[4-[3-[[[4-[(4-aminophenyl)sulfonyl]phenyl]amino]propoxy]-3,5-dimethoxyphenyl]methyl]-2,4-pyrimidinediamine), PD 138312 ((R)-7-[3-(1-amino-1-methylethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid), PD 140248 (7-[(3R)-3-[(1S)-1-aminoethyl]-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid), CP 111905 (5-deoxy-5-[[[(2E)-3-[3-hydroxy-4-(2-propenyloxy)phenyl]-2-methyl-1-oxo-2-propenyl]amino]-1,2-O-methylene-D-neo-inositol), Sulopenem ((5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), ritipenam acoxyl ((5R,6R)-3-[[[(aminocarbonyl)oxy]methyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (acetyloxy)methyl ester), RO-65-5788 ((6R,7R)-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(hydroxyimino)acetyl]amino]-3-[(E)-[(3'R)-1'-[[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl]-8-oxo-5-thia-1-

U.S. Application No. 09/738,742

Attorney Docket No. C058

azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monosodium salt), Sch-40832 (N-[[48-[1-[[2,6-dideoxy-3-O-(2,6-dideoxy-D-arabino-hexopyranosyl)-D-arabino-hexopyranosyl]oxy]ethyl]-15-ethylidene-1,3a,4,5,10,11,12,13,14,15,19,20,21,22,28,29,41,42-octadecahydro-41-hydroxy-12,45-bis(1-hydroxyethyl)-1-(hydroxymethyl)-22-(1-hydroxy-1-methylpropyl)-36-methyl-51,54,57-tris(methylene)-3-(methylthio)-10,13,20,27,38,49,52,55,58-nonaixo-18H,27H-5a,29-(iminocethaniminoethaniminoethaniminoethanimino[7,2]quinolinomethanoxy methano)-9,6:19,16:26,23:33,30-tetranitrilo-16H,33aH-imidazo[1',5':1,6]pyrido [3,2-m][1,11,17,24,4,7,20,27]tetrathiatetraazacyclotriacotin-1-yl]carbonyl]-2,3-didehydroalanyl-2,3-didehydroalanine methyl ester stereoisomer), micacocidin A ((OC-6-26-A)-[(4S)-2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-[2-(hydroxy-.kappa.O)-6-pentylphenyl]-4-thiazolyl-.kappa.N3]-3-methyl-4-thiazolidinyl-.kappa.N3]-2-(hydroxy-.kappa.O)-1,1-dimethylethyl]-4,5-dihydro-4-methyl-4-thiazolecarboxylato(2-)-.kappa.N3, .kappa.O4]-Zinc), SR-15402 ((1S,5S,8aS,8bR)-1,2,5,6,7,8,8a,8b-octahydro-1-[(1R)-1-hydroxyethyl]-2-oxo-5-[(3S)-3-pyrrolidinylthio]-azeto[2,1-a]isoindole-4-carboxylic acid), SUN A0026, TOC 39 (1-(2-amino-2-oxoethyl)-4-[[[(1E)-2-[(6R,7R)-7-[(2Z)-(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]ethenyl]thio]-pyridinium inner salt), carumonam ([[(Z)-[2-[(2S,3S)-2-[[[(aminocarbonyl)oxy]methyl]-4-oxo-1-sulfo-3-azetidiny]amino]-1-(2-amino-4-thiazolyl)-2-oxoethylidene]amino]oxy]-acetic acid), Cefozopran (1-[[[(6R,7R)-7-[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(methoxy imino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-imidazo[1,2-b]pyridazinium inner salt), Cefetamet pivoxil ((6R,7R)-7-[(2Z)-(2-amino-4-thiazolyl)(methoxy imino)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (2,2-dimethyl-1-oxopropoxy)methyl ester), and T 3811 (des-F(6)-quinolone).

U.S. Application No. 09/738,742

Attorney Docket No. C058

24. (Currently amended) The method according to claim 22, wherein said antimicrobial agent is selected from the group consisting of imipenen, amikacin, netilmicin, fosfomycin, gentamicin, ceftriaxone, teicoplanin, Ziracin (56-deacetyl-57-demethyl-45-O-de(2-methyl-1-oxopropyl)-12-O-(2,3,6-trideoxy-3-C-methyl-4-O-methyl-3-nitro-alpha-L-arabino-hexopyranosyl)flambamycin), LY333328 (oritavancin), CL 331002, HMR3647 HMR-3647 (3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl][4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]-erythromycin), Linezolid (N-[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide), Synercid (dalfopristin-quinupristin), Aztreonam (2-[(Z)-[1-(2-amino-4-thiazolyl)-2-[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidiny]] amino]-2-oxoethylidene]amino]oxy]-2-methyl-propanoic acid), and Metronidazole (2-methyl-5-nitro-1H-imidazole-1-ethanol).


25. (Currently amended) The method according to claim 17, wherein said subject is selected from the group consisting of a human ~~or~~ and an animal.

26. (Original) The method according to claim 25, wherein said subject is a human.

27. (Previously presented) The compound of claim 1 having the formula (II):

U.S. Application No. 09/738,742

Attorney Docket No. C058




wherein R⁵⁶ is an optionally substituted straight-chain C₈-C₁₄ alkyl group.

Claims 28-29 (Canceled)

30. (Currently amended) A method of using the compound according to claim 27 to make a compound according to either of claims 1 or 2 of the formula:

U.S. Application No. 09/738,742

Attorney Docket No. C058





























31. (Previously presented) The compound according to either of claims 1 or 2 wherein said compound is selected from

Cpd #	R	R ¹	R ²
1	NHCONH(CH ₂) ₇ CH ₃	NH ₂	
2	NHCONH(CH ₂) ₁₁ CH ₃	NH ₂	
3	NHCONH(CH ₂) ₁₀ CH ₃		























U.S. Application No. 09/738,742

Attorney Docket No. C058

5			
17	NHCONH(CH ₂) ₁₁ CH ₃		
48	NHCONH(CH ₂) ₁₀ CH ₃	NH ₂	
56	NHCONH(CH ₂) ₇ CH ₃		
57	NHCONH(CH ₂) ₁₀ CH ₃		
58	NHCONH(CH ₂) ₁₁ CH ₃		
62	NHCONH(CH ₂) ₇ CH ₃		
63	NHCONH(CH ₂) ₁₀ CH ₃		
64	NHCONH(CH ₂) ₁₁ CH ₃		
69	NHCONH(CH ₂) ₇ CH ₃		
70	NHCONH(CH ₂) ₇ CH ₃		
71	NHCONH(CH ₂) ₇ CH ₃		
75	NHCONH(CH ₂) ₁₀ CH ₃		

U.S. Application No. 09/738,742

Attorney Docket No. C058









76	NHCONH(CH ₂) ₇ CH ₃		
77	NHCONH(CH ₂) ₇ CH ₃		
78	NHCONH(CH ₂) ₇ CH ₃		
87	NHCONH(CH ₂) ₁₁ CH ₃		
88	NHCONH(CH ₂) ₁₁ CH ₃		
89	NHCONH(CH ₂) ₁₁ CH ₃		
108	NHCONH(CH ₂) ₁₀ CH ₃		
113	NHCONH(CH ₂) ₁₀ CH ₃		
114	NHCONH(CH ₂) ₁₀ CH ₃		
117	NHCONH(CH ₂) ₈ CH ₃	NHBoc	
118	NHCONH(CH ₂) ₈ CH ₃	NH ₂	
119	NHCONH(CH ₂) ₉ CH ₃	NHBoc	
120	NHCONH(CH ₂) ₉ CH ₃	NH ₂	

32. (Previously presented) The compound according to claim 31 wherein said


U.S. Application No. 09/738,742

Attorney Docket No. C058

compound is selected from

Cpd #	R	R ¹	R ²
2	NHCONH(CH ₂) ₁₁ CH ₃	NH ₂	
3	NHCONH(CH ₂) ₁₀ CH ₃		
48	NHCONH(CH ₂) ₁₀ CH ₃	NH ₂	
89	NHCONH(CH ₂) ₁₁ CH ₃		
118	NHCONH(CH ₂) ₈ CH ₃	NH ₂	
120	NHCONH(CH ₂) ₉ CH ₃	NH ₂	

33. (Previously presented) The compound according claim 2, wherein R is selected from the group consisting of:




wherein each of R³ and R⁵ is independently selected from the group consisting of hydrido, alkyl, aryl, heterocyclyl and heteroaryl, and wherein R²⁰⁰ is aryl.

U.S. Application No. 09/738,742


Attorney Docket No. C058

34. (Currently amended) The compound according to claim 33, wherein R is



and wherein R' is selected from the group consisting of a substituted phenyl.

35. (Previously presented) The compound according to claim 34, wherein R is



and wherein X^3 is chloro or trifluoromethyl.

36. (Currently amended) The method according to claim 23, wherein anti-folate agents are sulfonamides or synthetic antibacterials are selected from the group consisting of nitrofurans, methenamine mandelate and methenamine hippurate.